Celltrion Healthcare Inc., of Incheon, South Korea, said detailed results from NOR-SWITCH, a randomized, double-blind, switching study of anti-tumor necrosis factor-alpha biosimilar infliximab (Remicade, Janssen Biotech Inc.) were published in The Lancet. Sponsored by the Norwegian government, the study explored the impact of switching adult patients who were stable on reference infliximab to Celltrion's biosimilar CT-P13 (Remsima/Inflectra). The results demonstrate that CT-P13 is not inferior to continued treatment with the reference product and that patients can be safely switched.